A First Look at Phase 2 ArMaDa Data

Arshad M. Khanani, MD, FASRS, discusses phase 2 findings for OCU410, an investigational gene therapy for geographic atrophy. A phase 3 program is expected to begin later this year.

By
Arshad M. Khanani, MD, MA, FASRS
July 15, 2026
2 min

Retinal Physician

Top Institutions in Ophthalmology

Brief introduction explaining scope and methodology.

#1

University of California, Los Angeles (UCLA) Health

Los Angeles, CA
Key Differentiators
- Oncology
#2

Sierra Eye Associates

Sierra Vista, AZ
Key Differentiators
- Ophthalmology
#3

The University of Texas MD Anderson Cancer Center

Houston, TX
Key Differentiators
- Oncology
#4

Cleveland Clinic Lerner College of Medicine

Cleveland, OH
Key Differentiators
- Hematology
- Oncology
#5

Dana-Farber Cancer Institute

Boston, MA
Key Differentiators
- Oncology